Form 8-K Amendment

0001188112-06-000541.txt : 20060227 0001188112-06-000541.hdr.sgml : 20060227 20060227152803 ACCESSION NUMBER: 0001188112-06-000541 CONFORMED SUBMISSION TYPE: 8-K/A PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20060222 ITEM INFORMATION: Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20060227 DATE AS OF CHANGE: 20060227 FILER: COMPANY DATA: COMPANY CONFORMED NAME: THERAGENICS CORP CENTRAL INDEX KEY: 0000795551 STANDARD INDUSTRIAL CLASSIFICATION: INSTRUMENTS FOR MEAS & TESTING OF ELECTRICITY & ELEC SIGNALS [3825] IRS NUMBER: 581528626 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-14339 FILM NUMBER: 06646405 BUSINESS ADDRESS: STREET 1: 5203 BRISTOL INDUSTRIAL WAY CITY: BUFORD STATE: GA ZIP: 30518 BUSINESS PHONE: 7702710233 MAIL ADDRESS: STREET 1: 5203 BRISTOL INDUSTRIAL WAY CITY: BUFORD STATE: GA ZIP: 30518 FORMER COMPANY: FORMER CONFORMED NAME: NUCLEAR MEDICINE INC DATE OF NAME CHANGE: 19860902 8-K/A 1 t9136_8ka.htm FORM 8-K AMENDMENT Form 8-K Amendment

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K/A

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report: February 22, 2006

THERAGENICS CORPORATION^®

(Exact name of registrant as specified in charter)

Delaware	000-15443	58-1528626
(State of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

5203 Bristol Industrial Way

Buford, Georgia 30518

(Address of principal executive offices / Zip Code)

(770) 271-0233

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o	Written communications pursuant to Rule 425 under the Securities Act.

o	Soliciting material pursuant to Rule 14a-12 under the Exchange Act.

o	Pre-commencement communications pursuant to Rule 14d—2(b) under the Exchange Act.

o	Pre-commencement communications pursuant to Rule 13e—4(c) under the Exchange Act.

Item 5.02(b) Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers

In a filing on Form 8-K dated February 22, 2006, Theragenics Corporation (the “Company”) disclosed that on February 15, 2006, Mr. Earnest W. Deavenport, Jr. had orally notified the Company of his intent to not continue as a Director of the Company.

On February 23, 2006, Mr. Patrick L. Flinn, Chairman of the Board of Directors of the Company, received written correspondence from Mr. Deavenport, dated February 20, 2006, that he was retiring from the Board of Directors of the Company for personal reasons, effective with the Company’s 2006 Annual Meeting of Shareholders. The correspondence received from Mr. Deavenport is included herein as Exhibit 10.1.

Item 9.01 Financial Statements and Exhibits

Exhibit Number	Document

10.1	Correspondence dated February 20, 2006, received from Earnest W. Deavenport, Jr.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	THERAGENICS CORPORATION
	(Registrant)

Dated: February 27, 2006	By: /s/ M. Christine Jacobs
	M. Christine Jacobs
	Chief Executive Officer

EX-10.1 2 ex10-1.htm EXHIBIT 10.1 Exhibit 10.1

Exhibit 10.1

February 20, 2006

Mr. Pat L. Flinn

1050 N. Waterway Drive

Fort Meyers, FL 33919

Dear Pat,

For personal reasons I would like to retire from the Theragenics’ Board effective with the 2006 Annual Meeting.

Sincerely,

/s/ Earnest W. Deavenport, Jr.